|
1
|
Heim S and Mitelman F: Cancer
Cytogenetics: Chromosomal and Molecular Genetic Abberations of
Tumor Cells. Forth Edition. Wiley-Blackwell; 2015, http://dx.doi.org/10.1002/9781118795569.
View Article : Google Scholar
|
|
2
|
De Braekeleer E, Douet-Guilbert N, Morel
F, Le Bris MJ, Férec C and De Braekeleer M: RUNX1 translocations
and fusion genes in malignant hemopathies. Future Oncol. 7:77–91.
2011. View Article : Google Scholar
|
|
3
|
Yoshihara K, Wang Q, Torres-Garcia W,
Zheng S, Vegesna R, Kim H and Verhaak RG: The landscape and
therapeutic relevance of cancer-associated transcript fusions.
Oncogene. 34:4845–4854. 2015. View Article : Google Scholar :
|
|
4
|
Abe A, Katsumi A, Kobayashi M, Okamoto A,
Tokuda M, Kanie T, Yamamoto Y, Naoe T and Emi N: A novel
RUNX1-C11orf41 fusion gene in a case of acute myeloid leukemia with
a t(11;21)(p14;q22). Cancer Genet. 205:608–611. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bhojwani D, Pei D, Sandlund JT, Jeha S,
Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff S, Onciu M, Cheng C,
et al: ETV6-RUNX1-positive childhood acute lymphoblastic leukemia:
Improved outcome with contemporary therapy. Leukemia. 26:265–270.
2012. View Article : Google Scholar :
|
|
6
|
Cho EK, Bang SM, Ahn JY, Yoo SM, Park PW,
Seo YH, Shin DB and Lee JH: Prognostic value of AML 1/ETO fusion
transcripts in patients with acute myelogenous leukemia. Korean J
Intern Med. 18:13–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gandemer V, Chevret S, Petit A, Vermylen
C, Leblanc T, Michel G, Schmitt C, Lejars O, Schneider P, Demeocq
F, et al FRALLE Group: Excellent prognosis of late relapses of
ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: Lessons
from the FRALLE 93 protocol. Haematologica. 97:1743–1750. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sangle NA and Perkins SL: Core-binding
factor acute myeloid leukemia. Arch Pathol Lab Med. 135:1504–1509.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ji J, Loo E, Pullarkat S, Yang L and
Tirado CA: Acute myeloid leukemia with t(7;21)(p22;q22) and 5q
deletion: A case report and literature review. Exp Hematol Oncol.
3:82014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Osato M: Point mutations in the RUNX1/AML1
gene: Another actor in RUNX leukemia. Oncogene. 23:4284–4296. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Silva FP, Swagemakers SM,
Erpelinck-Verschueren C, Wouters BJ, Delwel R, Vrieling H, van der
Spek P, Valk PJ and Giphart-Gassler M: Gene expression profiling of
minimally differentiated acute myeloid leukemia: M0 is a distinct
entity subdivided by RUNX1 mutation status. Blood. 114:3001–3007.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dicker F, Haferlach C, Kern W, Haferlach T
and Schnittger S: Trisomy 13 is strongly associated with AML1/RUNX1
mutations and increased FLT3 expression in acute myeloid leukemia.
Blood. 110:1308–1316. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Harada H, Harada Y, Niimi H, Kyo T, Kimura
A and Inaba T: High incidence of somatic mutations in the
AML1/RUNX1 gene in myelodysplastic syndrome and low blast
percentage myeloid leukemia with myelodysplasia. Blood.
103:2316–2324. 2004. View Article : Google Scholar
|
|
14
|
Mendler JH, Maharry K, Radmacher MD,
Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J,
Kohlschmidt J, et al: RUNX1 mutations are associated with poor
outcome in younger and older patients with cytogenetically normal
acute myeloid leukemia and with distinct gene and MicroRNA
expression signatures. J Clin Oncol. 30:3109–3118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schnittger S, Dicker F, Kern W, Wendland
N, Sundermann J, Alpermann T, Haferlach C and Haferlach T: RUNX1
mutations are frequent in de novo AML with noncomplex karyotype and
confer an unfavorable prognosis. Blood. 117:2348–2357. 2011.
View Article : Google Scholar
|
|
16
|
Silva FP, Lind A, Brouwer-Mandema G, Valk
PJ and Giphart-Gassler M: Trisomy 13 correlates with RUNX1 mutation
and increased FLT3 expression in AML-M0 patients. Haematologica.
92:1123–1126. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nucifora G, Begy CR, Erickson P, Drabkin
HA and Rowley JD: The 3;21 translocation in myelodysplasia results
in a fusion transcript between the AML1 gene and the gene for EAP,
a highly conserved protein associated with the Epstein-Barr virus
small RNA EBER 1. Proc Natl Acad Sci USA. 90:7784–7788. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zent CS, Mathieu C, Claxton DF, Zhang DE,
Tenen DG, Rowley JD and Nucifora G: The chimeric genes AML1/MDS1
and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but
only AML1/MDS1 has tumor-promoter properties. Proc Natl Acad Sci
USA. 93:1044–1048. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hromas R, Busse T, Carroll A, Mack D,
Shopnick R, Zhang DE, Nakshatri H and Richkind K: Fusion AML1
transcript in a radiation-associated leukemia results in a
truncated inhibitory AML1 protein. Blood. 97:2168–2170. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ramsey H, Zhang DE, Richkind K,
Burcoglu-O'Ral A and Hromas R: Fusion of AML1/Runx1 to copine VIII,
a novel member of the copine family, in an aggressive acute
myelogenous leukemia with t(12;21) translocation. Leukemia.
17:1665–1666. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mikhail FM, Coignet L, Hatem N, Mourad ZI,
Farawela HM, El Kaffash DM, Farahat N and Nucifora G: A novel gene,
FGA7, is fused to RUNX1/AML1 in a t(4;21)(q28;q22) in a patient
with T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer.
39:110–118. 2004. View Article : Google Scholar
|
|
22
|
Ågerstam H, Lilljebjörn H, Lassen C,
Swedin A, Richter J, Vandenberghe P, Johansson B and Fioretos T:
Fusion gene-mediated truncation of RUNX1 as a potential mechanism
underlying disease progression in the 8p11 myeloproliferative
syndrome. Genes Chromosomes Cancer. 46:635–643. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Giguère A and Hébert J: CLCA2, a novel
RUNX1 partner gene in a therapy-related leukemia with
t(1;21)(p22;q22). Cancer Genet Cytogenet. 202:94–100. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Giguère A and Hébert J: Identification of
a novel fusion gene involving RUNX1 and the antisense strand of
SV2B in a BCR-ABL1-positive acute leukemia. Genes Chromosomes
Cancer. 52:1114–1122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rodriguez-Perales S, Torres-Ruiz R, Suela
J, Acquadro F, Martin MC, Yebra E, Ramirez JC, Alvarez S and
Cigudosa JC: Truncated RUNX1 protein generated by a novel
t(1;21)(p32;q22) chromosomal translocation impairs the
proliferation and differentiation of human hematopoietic
progenitors. Oncogene. 35:125–134. 2016. View Article : Google Scholar
|
|
26
|
Chinen Y, Taki T, Nishida K, Shimizu D,
Okuda T, Yoshida N, Kobayashi C, Koike K, Tsuchida M, Hayashi Y, et
al: Identification of the novel AML1 fusion partner gene, LAF4, a
fusion partner of MLL, in childhood T-cell acute lymphoblastic
leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA.
Oncogene. 27:2249–2256. 2008. View Article : Google Scholar
|
|
27
|
Dai HP, Xue YQ, Zhou JW, Li AP, Wu YF, Pan
JL, Wang Y and Zhang J: LPXN, a member of the paxillin superfamily,
is fused to RUNX1 in an acute myeloid leukemia patient with a
t(11;21)(q12;q22) translocation. Genes Chromosomes Cancer.
48:1027–1036. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hazourli S, Chagnon P, Sauvageau M, Fetni
R, Busque L and Hébert J: Overexpression of PRDM16 in the presence
and absence of the RUNX1/PRDM16 fusion gene in myeloid leukemias.
Genes Chromosomes Cancer. 45:1072–1076. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
LaFiura KM, Edwards H, Taub JW, Matherly
LH, Fontana JA, Mohamed AN, Ravindranath Y and Ge Y; Children's
Oncology Group: Identification and characterization of novel
AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid
leukemia: A report from the Children's Oncology Group. Oncogene.
27:4933–4942. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sakai I, Tamura T, Narumi H, Uchida N,
Yakushijin Y, Hato T, Fujita S and Yasukawa M: Novel RUNX1-PRDM16
fusion transcripts in a patient with acute myeloid leukemia showing
t(1;21)(p36;q22). Genes Chromosomes Cancer. 44:265–270. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stevens-Kroef MJ, Schoenmakers EF, van
Kraaij M, Huys E, Vermeulen S, van der Reijden B and van Kessel AG:
Identification of truncated RUNX1 and RUNX1-PRDM16 fusion
transcripts in a case of t(1;21)(p36;q22)-positive therapy-related
AML. Leukemia. 20:1187–1189. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Panagopoulos I, Gorunova L, Brandal P,
Garnes M, Tierens A and Heim S: Myeloid leukemia with
t(7;21)(p22;q22) and 5q deletion. Oncol Rep. 30:1549–1552.
2013.PubMed/NCBI
|
|
33
|
Jeandidier E, Gervais C, Radford-Weiss I,
Zink E, Gangneux C, Eischen A, Galoisy AC, Helias C, Dano L,
Cammarata O, et al: A cytogenetic study of 397 consecutive acute
myeloid leukemia cases identified three with a t(7;21) associated
with 5q abnormalities and exhibiting similar clinical and
biological features, suggesting a new, rare acute myeloid leukemia
entity. Cancer Genet. 205:365–372. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Foster N, Paulsson K, Sales M, Cunningham
J, Groves M, O'Connor N, Begum S, Stubbs T, McMullan DJ, Griffiths
M, et al: Molecular characterisation of a recurrent, semi-cryptic
RUNX1 translocation t(7;21) in myelodysplastic syndrome and acute
myeloid leukaemia. Br J Haematol. 148:938–943. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Paulsson K, Békássy AN, Olofsson T,
Mitelman F, Johansson B and Panagopoulos I: A novel and
cytogenetically cryptic t(7;21) (p22;q22) in acute myeloid leukemia
results in fusion of RUNX1 with the ubiquitin-specific protease
gene USP42. Leukemia. 20:224–229. 2006. View Article : Google Scholar
|
|
36
|
Hasle H, Abrahamsson J, Forestier E, Ha
SY, Heldrup J, Jahnukainen K, Jónsson OG, Lausen B, Palle J and
Zeller B; Nordic Society of Paediatric Haematology Oncology
(NOPHO): Gemtuzumab ozogamicin as postconsolidation therapy does
not prevent relapse in children with AML: Results from NOPHO-AML
2004. Blood. 120:978–984. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schaffer LG, Slovak ML and Campbell LJ:
ISCN 2009: An International System for Human Cytogenetic
Nomenclature. Karger S: Basel: 2009
|
|
38
|
McPherson A, Hormozdiari F, Zayed A,
Giuliany R, Ha G, Sun MG, Griffith M, Heravi Moussavi A, Senz J,
Melnyk N, et al: deFuse: An algorithm for gene fusion discovery in
tumor RNA-Seq data. PLOS Comput Biol. 7:e10011382011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Singhal H, Ren YR and Kern SE: Improved
DNA electrophoresis in conditions favoring polyborates and lewis
acid complexation. PLoS One. 5:e113182010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ogawa E, Maruyama M, Kagoshima H, Inuzuka
M, Lu J, Satake M, Shigesada K and Ito Y: PEBP2/PEA2 represents a
family of transcription factors homologous to the products of the
Drosophila runt gene and the human AML1 gene. Proc Natl Acad Sci
USA. 90:6859–6863. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Miyoshi H, Shimizu K, Kozu T, Maseki N,
Kaneko Y and Ohki M: t(8;21) breakpoints on chromosome 21 in acute
myeloid leukemia are clustered within a limited region of a single
gene, AML1. Proc Natl Acad Sci USA. 88:10431–10434. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Miyoshi H, Ohira M, Shimizu K, Mitani K,
Hirai H, Imai T, Yokoyama K, Soeda E and Ohki M: Alternative
splicing and genomic structure of the AML1 gene involved in acute
myeloid leukemia. Nucleic Acids Res. 23:2762–2769. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tanaka T, Tanaka K, Ogawa S, Kurokawa M,
Mitani K, Nishida J, Shibata Y, Yazaki Y and Hirai H: An acute
myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell
differentiation and transcriptional activation antagonistically by
two alternative spliced forms. EMBO J. 14:341–350. 1995.PubMed/NCBI
|
|
44
|
Niitsu N, Yamamoto-Yamaguchi Y, Miyoshi H,
Shimizu K, Ohki M, Umeda M and Honma Y: AML1a but not AML1b
inhibits erythroid differentiation induced by sodium butyrate and
enhances the megakaryocytic differentiation of K562 leukemia cells.
Cell Growth Differ. 8:319–326. 1997.PubMed/NCBI
|
|
45
|
Ran D, Shia WJ, Lo MC, Fan JB, Knorr DA,
Ferrell PI, Ye Z, Yan M, Cheng L, Kaufman DS, et al: RUNX1a
enhances hematopoietic lineage commitment from human embryonic stem
cells and inducible pluripotent stem cells. Blood. 121:2882–2890.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tsuzuki S, Hong D, Gupta R, Matsuo K, Seto
M and Enver T: Isoform-specific potentiation of stem and progenitor
cell engraftment by AML1/RUNX1. PLoS Med. 4:e1722007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu X, Zhang Q, Zhang DE, Zhou C, Xing H,
Tian Z, Rao Q, Wang M and Wang J: Overexpression of an isoform of
AML1 in acute leukemia and its potential role in leukemogenesis.
Leukemia. 23:739–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Watanabe-Okochi N, Kitaura J, Ono R,
Harada H, Harada Y, Komeno Y, Nakajima H, Nosaka T, Inaba T and
Kitamura T: AML1 mutations induced MDS and MDS/AML in a mouse BMT
model. Blood. 111:4297–4308. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dowdy CR, Xie R, Frederick D, Hussain S,
Zaidi SK, Vradii D, Javed A, Li X, Jones SN, Lian JB, et al:
Definitive hematopoiesis requires Runx1 C-terminal-mediated
subnuclear targeting and transactivation. Hum Mol Genet.
19:1048–1057. 2010. View Article : Google Scholar :
|
|
50
|
Gupta V, Minden MD, Yi QL, Brandwein J and
Chun K: Prognostic significance of trisomy 4 as the sole
cytogenetic abnormality in acute myeloid leukemia. Leuk Res.
27:983–991. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Klein K, Kaspers G, Harrison CJ, Beverloo
HB, Reedijk A, Bongers M, Cloos J, Pession A, Reinhardt D,
Zimmerman M, et al: Clinical impact of additional cytogenetic
aberrations, cKIT- and RAS mutations and other factors in pediatric
t(8;21)-AML: Results from an International Retrospective Study by
the International Berlin-Frankfutrt-Munster Study Group. J Clin
Oncol. 33:4247–4258. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Levis M: FLT3 mutations in acute myeloid
leukemia: What is the best approach in 2013? Hematology Am Soc
Hematol Educ Program. 2013:220–226. 2013.PubMed/NCBI
|
|
53
|
Döhner H, Estey EH, Amadori S, Appelbaum
FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson
RA, et al European LeukemiaNet: Diagnosis and management of acute
myeloid leukemia in adults: Recommendations from an international
expert panel, on behalf of the European LeukemiaNet. Blood.
115:453–474. 2010. View Article : Google Scholar
|
|
54
|
Estey EH: Acute myeloid leukemia: 2014
update on risk-stratification and management. Am J Hematol.
89:1063–1081. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Allen C, Hills RK, Lamb K, Evans C,
Tinsley S, Sellar R, O'Brien M, Yin JL, Burnett AK, Linch DC, et
al: The importance of relative mutant level for evaluating impact
on outcome of KIT, FLT3 and CBL mutations in core-binding factor
acute myeloid leukemia. Leukemia. 27:1891–1901. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jourdan E, Boissel N, Chevret S, Delabesse
E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C,
Raffoux E, et al French AML Intergroup: Prospective evaluation of
gene mutations and minimal residual disease in patients with core
binding factor acute myeloid leukemia. Blood. 121:2213–2223. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Meshinchi S, Alonzo TA, Stirewalt DL,
Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJ, Heerema NA, Gerbing
R, Lange BJ, et al: Clinical implications of FLT3 mutations in
pediatric AML. Blood. 108:3654–3661. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zwaan CM, Meshinchi S, Radich JP, Veerman
AJ, Huismans DR, Munske L, Podleschny M, Hählen K, Pieters R,
Zimmermann M, et al: FLT3 internal tandem duplication in 234
children with acute myeloid leukemia: Prognostic significance and
relation to cellular drug resistance. Blood. 102:2387–2394. 2003.
View Article : Google Scholar : PubMed/NCBI
|
